SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Top Pharma Companies in India by Market Cap

BSE Sensex 76831.75
4.03 (-0.01%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
1	Abbott India Ltd.	Q V PT	59,102 Mid Cap	27,813.40 (0.00%)	38.08	12.45	9.96	17.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
2	Neuland Laboratories Ltd.	Q V+ PT	24,345 Small Cap	18,975.40 (0.00%)	67.05	13.05	16.64	37.61	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
3	Apollo Hospitals Enterprise Ltd.	Q V+ PT	1,27,149 Large Cap	8,922.05 (0.89%)	85.19	12.76	-3.49	29.94	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
4	Astrazeneca Pharma India Ltd.	Q V PT	20,420 Small Cap	8,167.90 (0.00%)	108.89	23.57	22.84	15.69	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
5	Divis Laboratories Ltd.	Q V+ PT	1,96,881 Large Cap	7,489 (0.98%)	76.67	11.75	8.67	4.44	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
6	Procter & Gamble Health Ltd.	Q V+ PT	11,257 Small Cap	6,781.40 (0.00%)	34.43	21.46	4.31	11.97	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
7	Kovai Medical Center & Hospital Ltd.	Q V PT	6,411 Small Cap	5,858.50 (0.00%)	26.22	4.86	14.01	17.17	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
8	Alkem Laboratories Ltd.	Q V+ PT	67,124 Mid Cap	5,600.05 (-0.25%)	30.72	4.8	5.71	10.33	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
9	Dr Agarwals Eye Hospital Ltd.	Q V PT	2,436 Small Cap	5,041.05 (0.00%)	34.75	7.04	17.68	31.54	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
10	Torrent Pharmaceuticals Ltd.	Q V+ PT	1,90,832 Large Cap	5,017.05 (0.00%)	88.21	22.69	11.80	13.74	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
11	Pfizer Ltd.	Q V PT	21,456 Small Cap	4,728.35 (0.81%)	29.7	5.11	2.39	8.89	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
12	Sanofi Consumer Healthcare India Ltd.	Q V+ PT	10,773 Small Cap	4,677.85 (0.00%)	41.77	23.84	0.00	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
13	Ajanta Pharma Ltd.	Q V+ PT	42,278 Mid Cap	3,385 (0.03%)	40.04	9.35	13.54	10.92	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
14	Sanofi India Ltd.	Q V PT	7,760 Small Cap	3,369.25 (0.00%)	25.05	9.95	-8.74	-7.50	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
15	Acutaas Chemicals Ltd.	Q V+ PT	27,579 Small Cap	3,353.45 (-0.45%)	69.39	15.81	32.80	16.82	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
16	RPG Life Sciences Ltd.	Q V+ PT	4,827 Small Cap	2,916.15 (-0.08%)	41.91	7.97	12.70	21.72	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
17	Kwality Pharmaceuticals Ltd.	Q V+ PT	2,815 Small Cap	2,715.05 (0.07%)	41.8	8.47	21.70	37.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
18	Caplin Point Laboratories Ltd.	Q V PT	19,939 Small Cap	2,631.10 (0.30%)	31.09	5.56	17.55	21.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
19	Mankind Pharma Ltd.	Q V PT	1,05,357 Mid Cap	2,569.70 (0.73%)	51.71	6.44	13.54	13.36	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
20	Glaxosmithkline Pharmaceuticals Ltd.	Q V PT	43,202 Mid Cap	2,541.50 (-0.34%)	41.7	18.92	5.49	17.52	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
21	Hester Biosciences Ltd.	Q V PT	2,151 Small Cap	2,528.50 (0.00%)	41.29	5.58	6.98	0.80	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
22	Lupin Ltd.	Q V PT	1,10,189 Mid Cap	2,423.90 (0.58%)	20.66	4.92	13.02	32.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
23	Gland Pharma Ltd.	Q V PT	40,049 Small Cap	2,415.65 (-0.50%)	30.82	3.7	9.35	7.37	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
24	Glenmark Pharmaceuticals Ltd.	Q V+ PT	61,928 Mid Cap	2,194.65 (0.01%)	45.47	5.89	4.60	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
25	CORONA Remedies Ltd.	Q V+ PT	12,807 Small Cap	2,115 (1.00%)	69.28	17.17	19.49	18.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
26	Narayana Hrudayalaya Ltd.	Q V PT	41,974 Mid Cap	2,073.95 (0.98%)	52.1	9.25	25.04	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
27	Sun Pharmaceutical Industries Ltd.	Q V+ PT	4,73,509 Large Cap	1,987.70 (0.72%)	41.25	5.67	11.78	14.41	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
28	Emcure Pharmaceuticals Ltd.	Q V+ PT	36,490 Small Cap	1,923 (-0.04%)	49.78	9.83	13.02	9.98	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
29	Wockhardt Ltd.	Q V+ PT	30,311 Small Cap	1,863.95 (-0.08%)	142.31	6.15	4.49	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
30	Dr. Lal Pathlabs Ltd.	Q V PT	30,607 Small Cap	1,829.75 (0.22%)	56.18	11.9	12.18	13.26	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
Fischer Medical	38.57	2.44%
KMC Speciality Hosp.	133	1.95%
Blue Jet Healthcare	585.45	1.61%
Max Healthcare Inst.	1,129.05	1.30%
Syngene Internatl.	418.85	1.18%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Nectar Lifesciences	10.06	-3.45%
Fermenta Biotech	433	-2.48%
Themis Medicare	106.45	-1.48%
Wanbury	326.50	-1.42%
Bliss GVS Pharma	455	-1.30%

News about Top Pharma Companies in India

Jul, 2026

Gland Pharma informs about board meeting

Gland Pharma has informed that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026, inter alia, to consider and approve Unaudited Standalone and Consolidated Financial results of the Company for the quarter ended June 30, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Dr. Lal Pathlabs - Quaterly Results

The company witnessed a 19.31% growth in the revenue at Rs. 7644.00 millions for the quarter ended June 2026 as compared to Rs. 6407.00 millions during the year-ago period.The company has announced a 28.31% increase in its profits to Rs . 1659.00 millions for the quarter ended June 2026 compared to Rs. 1293.00 millions in the corresponding quarter in the previous year.Operating Profit saw a handsome growth to 2684.00 millions from 2097.00 millions in the quarter ended June 2026.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	7644.00	6407.00	19.31	7644.00	6407.00	19.31	26476.00	23516.00	12.59
Other Income	299.00	263.00	13.69	299.00	263.00	13.69	1127.00	1115.00	1.08
PBIDT	2684.00	2097.00	27.99	2684.00	2097.00	27.99	8664.00	7770.00	11.51
Interest	61.00	45.00	35.56	61.00	45.00	35.56	220.00	215.00	2.33
PBDT	2623.00	2052.00	27.83	2623.00	2052.00	27.83	8143.00	7555.00	7.78
Depreciation	400.00	328.00	21.95	400.00	328.00	21.95	1541.00	1342.00	14.83
PBT	2223.00	1724.00	28.94	2223.00	1724.00	28.94	6602.00	6213.00	6.26
TAX	564.00	431.00	30.86	564.00	431.00	30.86	1520.00	1240.00	22.58
Deferred Tax	-9.00	22.00	-140.91	-9.00	22.00	-140.91	14.00	-393.00	-103.56
PAT	1659.00	1293.00	28.31	1659.00	1293.00	28.31	5082.00	4973.00	2.19
Equity	1676.00	838.00	100.00	1676.00	838.00	100.00	1676.00	836.00	100.48
PBIDTM(%)	35.11	32.73	7.28	35.11	32.73	7.28	32.72	33.04	-0.96

Jul, 2026

Acutaas Chemicals - Quaterly Results

The Turnover for the quarter ended June 2026 of Rs. 3224.09 millions increase by 56.53% from Rs. 2059.71 millions.Net profit for the quarter ended June 2026 increased significantly by 70.00% to Rs. 758.96 millions from Rs. 446.46 millions.Operating profit for the quarter ended June 2026 rose to 1141.53 millions as compared to 670.09 millions of corresponding quarter ended June 2025.

(Rs. in Million)

	Quarter ended			Year to Date			Year ended
	202606	202506	% Var	202606	202506	% Var	202603	202503	% Var
Sales	3224.09	2059.71	56.53	3224.09	2059.71	56.53	13237.92	9898.35	33.74
Other Income	44.76	160.20	-72.06	44.76	160.20	-72.06	458.78	183.36	150.21
PBIDT	1141.53	670.09	70.35	1141.53	670.09	70.35	5288.83	2434.78	117.22
Interest	11.18	6.20	80.32	11.18	6.20	80.32	30.77	58.57	-47.46
PBDT	1130.35	663.89	70.26	1130.35	663.89	70.26	5258.06	2376.21	121.28
Depreciation	90.20	74.62	20.88	90.20	74.62	20.88	330.32	240.45	37.38
PBT	1040.15	589.27	76.52	1040.15	589.27	76.52	4927.74	2135.76	130.73
TAX	281.19	142.81	96.90	281.19	142.81	96.90	1265.99	540.29	134.32
Deferred Tax	25.87	15.53	66.58	25.87	15.53	66.58	111.09	70.58	57.40
PAT	758.96	446.46	70.00	758.96	446.46	70.00	3661.75	1595.47	129.51
Equity	409.36	409.34	0.00	409.36	409.34	0.00	409.36	409.34	0.00
PBIDTM(%)	35.41	32.53	8.83	35.41	32.53	8.83	39.95	24.60	62.42

Jul, 2026

Divi's Laboratories informs about earnings call

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Divi's Laboratories has informed that it enclosed the schedule of earnings conference call for the quarter ended June 30, 2026, to be held on August 01, 2026.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sun Pharmaceutical Industries informs about press release

Sun Pharmaceutical Industries has informed that it enclosed a copy of the press release titled ‘Sun Pharma Notes Organon Shareholder Approval for Proposed Acquisition,’ which shall be released after this intimation.

The above information is a part of company’s filings submitted to BSE.

Jul, 2026

Sanofi India informs about analyst meet

Sanofi India has informed that the Company will hold an investor / analysts call for an update on Unaudited Financial Results for the quarter and half year ended 30th June 2026, the details enclosed.

The above information is a part of company’s filings submitted to BSE.

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Abbott India Ltd.	59,102 Crore
2	Neuland Laboratories Ltd.	24,345 Crore
3	Apollo Hospitals Enterprise Ltd.	1,27,149 Crore
4	Astrazeneca Pharma India Ltd.	20,420 Crore
5	Divis Laboratories Ltd.	1,96,881 Crore
6	Procter & Gamble Health Ltd.	11,257 Crore
7	Kovai Medical Center & Hospital Ltd.	6,411 Crore
8	Alkem Laboratories Ltd.	67,124 Crore
9	Dr Agarwals Eye Hospital Ltd.	2,436 Crore
10	Torrent Pharmaceuticals Ltd.	1,90,832 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	27,813	59,102	38.08	12.45	26.07	34.24
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,017	1,90,832	88.21	22.69	45.79	29.04
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	26.43
Ajanta Pharma Ltd. (M)	Very Good	3,385	42,278	40.04	9.35	27.05	25.35
Alkem Laboratories Ltd. (M)	Very Good	5,600	67,124	30.72	4.80	22.28	17.86

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,714	92,623	105
Sai Life Sciences Ltd. (S)	Very Good	1,283	27,347	53.73
Torrent Pharmaceuticals Ltd. (L)	Very Good	5,017	1,90,832	39.27
Aurobindo Pharma Ltd. (M)	Very Good	1,543	89,115	38.01
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	23.52
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
Sai Life Sciences Ltd. (S)	Very Good	1,283	27,347	80.08	10.90	42.11	17.75
Ajanta Pharma Ltd. (M)	Very Good	3,385	42,278	40.04	9.35	27.05	13.54
Mankind Pharma Ltd. (M)	Very Good	2,570	1,05,357	51.71	6.44	32.38	13.54
Zydus Lifesciences Ltd. (M)	Very Good	1,106	1,10,523	21.93	4.25	13.45	13.52
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	13.02

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Lupin Ltd. (M)	Somewhat Good	2,424	1,10,189	20.66	4.92	11.95	32.37
Abbott India Ltd. (M)	Very Good	27,813	59,102	38.08	12.45	26.07	17.33
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,147	96,063	29.81	2.52	15.31	15.75
Zydus Lifesciences Ltd. (M)	Very Good	1,106	1,10,523	21.93	4.25	13.45	14.72
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,988	4,73,509	41.25	5.67	23.65	14.41

You have 7 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Top Pharma Companies in India by Market Cap

News about Top Pharma Companies in India

Gland Pharma informs about board meeting

Dr. Lal Pathlabs - Quaterly Results

Acutaas Chemicals - Quaterly Results

Divi's Laboratories informs about earnings call

Sun Pharmaceutical Industries informs about press release

Sanofi India informs about analyst meet

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

How to select the top Nifty Pharma stocks based on RoE?

What are the best-performing stocks in the Nifty Pharma index?

Which Nifty Pharma stocks have the highest revenue growth in the past five years?

Which Nifty Pharma stocks had the highest profit growth in the past five years ?

Create stable, long-term investment portfolio with strong, consistent stocks.

About MoneyWorks4Me

Our Vision

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.